patrick.net
An Antidote to Corporate Media
1,191,576 comments by 13,863 users - 1337irr, Ceffer, Patrick, RWSGFY online now
Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with in-vitro effective drug ivermectin
invite response
2021 Sep 5, 10:07am 191 views 2 comments
Comments 1 - 2 of 2 Search these comments
1
Al_Sharpton_for_President
2021 Sep 5, 10:12am
Al_Sharpton_for_President
2021 Sep 5, 10:12am
A likely biological mechanism has been indicated to be competitive binding with SARS-CoV-2 spike protein sites, as reviewed [8,9].
[8] Scheim DE. From cold to killer: how SARS-CoV-2 evolved without
hemagglutinin esterase to agglutinate, then clot blood cells in pulmo- nary and systemic microvasculature SSRN. 2020. Available from: http:// ssrn.com/abstract=3706347. [Accessed 30 March 2021].
[9] Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of Iver- mectin against SARS-CoV-2: an evidence-based clinical review article. J Antib 2021. https://doi.org/10.1038/s41429-021-00430-5.
Recently, Dr Satoshi Omura, the Nobel co-laureate for the discovery of IVM, and colleagues conducted a comprehensive review of IVM clinical activity against COVID-19, concluding that the preponderance of the evidence demonstrated major reductions in mortality and morbidity [2]. Our review of that evidence, updated with consideration of several new studies, supports the same conclusion.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383101/pdf/main.pdf
[8] Scheim DE. From cold to killer: how SARS-CoV-2 evolved without
hemagglutinin esterase to agglutinate, then clot blood cells in pulmo- nary and systemic microvasculature SSRN. 2020. Available from: http:// ssrn.com/abstract=3706347. [Accessed 30 March 2021].
[9] Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of Iver- mectin against SARS-CoV-2: an evidence-based clinical review article. J Antib 2021. https://doi.org/10.1038/s41429-021-00430-5.
Recently, Dr Satoshi Omura, the Nobel co-laureate for the discovery of IVM, and colleagues conducted a comprehensive review of IVM clinical activity against COVID-19, concluding that the preponderance of the evidence demonstrated major reductions in mortality and morbidity [2]. Our review of that evidence, updated with consideration of several new studies, supports the same conclusion.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383101/pdf/main.pdf
2
Patrick
2021 Sep 5, 10:13am
Patrick
2021 Sep 5, 10:13am
Al_Sharpton_for_President says
Why is this not a headline in all the corporate media?
Ah yeah, they are not journalists but only propagandists, completely owned by the same groups that own the government and Big Pharma.
Ivermectin was reported to dramatically reduce the cell line of SARS-CoV-2 by ∼5000 folds within 48
Why is this not a headline in all the corporate media?
Ah yeah, they are not journalists but only propagandists, completely owned by the same groups that own the government and Big Pharma.
Among 12 different COVID-19 targets along with Importin-α studied here, the RNA dependent RNA polymerase (RdRp) with RNA and Helicase NCB site show the strongest affinity to Ivermectin amounting −10.4 kcal/mol and −9.6 kcal/mol, respectively, followed by Importin-α with −9.0 kcal/mol. Molecular dynamics of corresponding protein-drug complexes reveals that the drug bound state of RdRp with RNA has better structural stability than the Helicase NCB site and Importin-α, with MM/PBSA free energy of −187.3 kJ/mol, almost twice that of Helicase (−94.6 kJ/mol) and even lower than that of Importin-α (−156.7 kJ/mol). The selectivity of Ivermectin to RdRp is triggered by a cooperative interaction of RNA-RdRp by ternary complex formation. Identification of the target and its interaction profile with Ivermectin can lead to more powerful drug designs for COVID-19 and experimental exploration.
https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1839564